The efficacy of COVID-19 vaccines in chronic kidney disease and kidney transplantation patients: a narrative review
YC Hou, KC Lu, KL Kuo - Vaccines, 2021 - mdpi.com
The SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) pandemic has posed a
huge threat to global health because of its rapid spread and various mutant variants. Critical …
huge threat to global health because of its rapid spread and various mutant variants. Critical …
[HTML][HTML] Immunosuppressive therapy after solid organ transplantation and the gut microbiota: Bidirectional interactions with clinical consequences
P Gabarre, C Loens, Y Tamzali, B Barrou… - American Journal of …, 2022 - Elsevier
Our understanding of the involvement of the gut microbiota (GM) in human health has
expanded exponentially over the last few decades, particularly in the fields of metabolism …
expanded exponentially over the last few decades, particularly in the fields of metabolism …
Markers of inflammation and stress distinguish subsets of individuals with schizophrenia and bipolar disorder
Schizophrenia and bipolar disorder share a number of common features, both
symptomatically and biologically. Abnormalities in the neuroimmune and the stress …
symptomatically and biologically. Abnormalities in the neuroimmune and the stress …
Effects of antirejection drugs on innate immune cells after kidney transplantation
G Zaza, J Leventhal, L Signorini, G Gambaro… - Frontiers in …, 2019 - frontiersin.org
Over the last decades, our understanding of adaptive immune responses to solid organ
transplantation increased considerably and allowed development of immunosuppressive …
transplantation increased considerably and allowed development of immunosuppressive …
Immunosuppression in kidney transplantation: state of the art and current protocols
Currently, kidney transplantation is the best treatment option for kidney failure for a majority
of eligible patients. It is associated with a better quality of life and reduced mortality as …
of eligible patients. It is associated with a better quality of life and reduced mortality as …
Glucocorticoids use in kidney transplant setting
DD De Lucena, ÉB Rangel - Expert Opinion on Drug Metabolism & …, 2018 - Taylor & Francis
Introduction: Despite major advances in kidney transplant, glucocorticoids (GCs) or steroids
remain one of the mainstay treatments. They possess adverse events (AEs) that are related …
remain one of the mainstay treatments. They possess adverse events (AEs) that are related …
[HTML][HTML] Personalized immunosuppression in elderly renal transplant recipients
LEJ Peeters, LM Andrews, DA Hesselink… - Pharmacological …, 2018 - Elsevier
The number of elderly people has increased considerably over the last decades, due to a
rising life expectancy and ageing populations. As a result, an increased number of elderly …
rising life expectancy and ageing populations. As a result, an increased number of elderly …
A theoretical physiologically‐based pharmacokinetic approach to ascertain covariates explaining the large interpatient variability in tacrolimus disposition
C Emoto, TN Johnson, D Hahn… - CPT …, 2019 - Wiley Online Library
Physiologically‐based pharmacokinetic (PBPK) modeling allows assessment of the
covariates contributing to the large pharmacokinetic (PK) variability of tacrolimus; these …
covariates contributing to the large pharmacokinetic (PK) variability of tacrolimus; these …
Early corticosteroid cessation vs long-term corticosteroid therapy in kidney transplant recipients: long-term outcomes of a randomized clinical trial
Importance The complications of corticosteroids make the inclusion of these drugs in
immunosuppressive protocols for kidney transplant patients undesirable. However …
immunosuppressive protocols for kidney transplant patients undesirable. However …
Recent advances in liposomal-based anti-inflammatory therapy
CMA van Alem, JM Metselaar, C van Kooten… - Pharmaceutics, 2021 - mdpi.com
Liposomes can be seen as ideal carriers for anti-inflammatory drugs as their ability to
(passively) target sites of inflammation and release their content to inflammatory target cells …
(passively) target sites of inflammation and release their content to inflammatory target cells …